

GRANT AGREEMENT



Parties to this agreement:

**Diabetesforeningen**  
**Stationsparken 24, st. tv.**  
**2600 Glostrup**  
**Denmark**  
**CVR-nr. DK-35 23 15 28**

**Novo Nordisk Denmark A/S**  
Att.: Søren Beicker Sørensen  
Kay Fiskers Plads 10, 7 floor  
2300 København S  
CVR No. 38180045

**(“Recipient”)**

**(“Novo Nordisk”)**

1. Summary
- 1.1 Recipient’s request for support.** The appendix titled “Recipient’s request for support” details the specifics of the Recipient’s activity(ies) (“the Activity”) supported by the grant and purpose of the Activity. Novo Nordisk has decided to support the recipient’s request as part of its commitment to advance healthcare and science.

|                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Title of Activity</b>       | Sundhedspolitisk åbningsdebat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Purpose of the Activity</b> | <p>The recipient shall use the grant only for the healthcare-related purpose of framing a broader health policy debate ahead of the opening of the Danish Parliament. The conference focuses on the debate about health investments— and why health cannot be viewed solely as an expense— as well as initiatives decided in connection with the healthcare reform, including chronic care packages and the establishment of health councils.</p> <p><i>The recipient’s purpose must not involve promotion of any pharmaceutical product.</i></p> |
| <b>Grant amount</b>            | <p>Novo Nordisk will provide DKK 96.000 (inclusive of VAT), to support the Recipient’s request.</p> <p>Novo Nordisk will not make any non-financial transfers of value.</p>                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Agreement Duration</b>      | This agreement starts on 24 September 2026 and expires after all obligations are fulfilled, unless terminated earlier.                                                                                                                                                                                                                                                                                                                                                                                                                            |

2. Recipient’s Duties
- 2.1 Compliance with law and ethics.** The Recipient shall comply with all applicable laws, rules, regulations, and professional standards, including those related to ethical business practices, bribery and corruption, among others. The Recipient will hold Novo Nordisk harmless against any claim or suit that arises in relation to any deviation from the above mentioned that is not due to any act or omission by Novo Nordisk.

**2.2 Carry out the Activity with proper conduct.** The Recipient shall carry out the Activity independently and without Novo Nordisk influence, and in compliance with Novo Nordisk standards and industry codes such as IFPMA and EFPIA. Such proper conduct of the Activity includes, but is not limited to:

|                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>No use of funds for entertainment</b>                              | Do not use the grant for leisure or social activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| <b>No use of product names</b>                                        | Do not use trade and advertising names of medicinal products in any content or materials used for the Activity                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Select qualified participants</b>                                  | Apply appropriate criteria to select participants in the Activity, including that any speakers, facilitators, and chairpersons are experts in the professional fields relevant to the Activity                                                                                                                                                                                                                                                                                                                                                         |
| <b>Reasonable payment</b>                                             | If grant is used to provide payments to third parties, apply a reasonable rate, including following Fair Market Value for any payments to Healthcare Professionals (hereinafter refer to as 'HCPs') and patients. Grant shall not cover any honoraria towards any elected representatives.                                                                                                                                                                                                                                                             |
| <b>Reasonable choice of venue</b>                                     | Hold activities in a location suitable for business meetings with modest hospitality                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Reasonable travel</b>                                              | If grant is used for Activity-related travel, carry out within reasonable time and cost.<br>Novo Nordisk will only accept support to compensation of mileage to Health Care Professionals that follows ENLI's (Etisk Nævn for Lægemiddelindustrien) tariffs, ref. to §13, 7 in ENLI's Promotion Code. Support that goes towards compensation of car mileage as according to the state tariffs is not permitted.                                                                                                                                        |
| <b>Transparency about support towards participants</b>                | The invitation for the event must clearly state that the event is being supported by one or more pharmaceutical companies.                                                                                                                                                                                                                                                                                                                                                                                                                             |
| <b>Acknowledgement of obligations towards Danish Medicines Agency</b> | If Danish doctors, dentists or pharmacists are affiliated with the activity and receive honorarium from the support provided by Novo Nordisk these persons must be informed about their obligation to report this affiliation to Danish Medicines Agency.<br>The Recipient undertakes to fulfil this information duty and to give Novo Nordisk the following information: Name, authorisation ID, workplace, home address, affiliation start date, affiliation end date. Novo Nordisk must also report this information to the Danish Medicines Agency |

**2.3 Internal approvals.** The Recipient shall obtain all necessary approvals related to the receipt of the grant.

**2.4 Provide documentation within 1 month.** The Recipient shall provide Novo Nordisk with documentation that the grant was used for its intended purpose, within 1 month of completion of the Activity. Novo Nordisk may request additional detailed documentation as needed.

**2.5 Inform Novo Nordisk of changes.** The Recipient shall inform Novo Nordisk of any changes affecting the request for support. Novo Nordisk may increase, decrease, withdraw or require full or partial repayment of the grant as a result of the changes. In the case of repayment, the Recipient shall refund Novo Nordisk the requested amount within 14 days.

**2.6 Refund unspent amounts.** The Recipient shall refund Novo Nordisk any amounts not spent for the requested purposes, within 14 days after complete documentation of the Activity is provided.

**2.7 Disclose Novo Nordisk as grant provider.** The Recipient shall mention Novo Nordisk as the provider of the grant in educational materials developed through the grant, as well as in any public communications or advertising related to the Activity.

**2.8 Required public disclosures.** Novo Nordisk will publish information relating to this grant on Novo Nordisk's website ([www.novonordisk.dk](http://www.novonordisk.dk)). According to Danish regulation Novo Nordisk may in addition make this Grant Agreement publicly available. The Recipient shall provide to Novo Nordisk

upon request all information reasonably required for Novo Nordisk's compliance with legal and/or regulatory requirements for contracting, tracking and disclosing transfer of values (ToVs) to the Recipient.

The Recipient will publish information on the grant on the Recipient's webpage. The information includes the grants amount and, if applicable, any in kind transfer, cf. the Danish Pharmaceutical Promotional Act (Reklamebekendtgørelsen) § 21. The information must be available on the Recipient's webpage no later than one (1) month after the Recipient received the Grant. The information must be publicly available for at least two (2) years.

**2.9 Do not use Novo Nordisk branding without approval.** The Recipient may not use Novo Nordisk's logo, trademarks or other corporate identity marks or materials without written approval of the use from Novo Nordisk.

**2.10 Allow Novo Nordisk to use Recipient's logo.** The Recipient permits Novo Nordisk to use the Recipient's logo, trademarks or other corporate identity marks in any public communications or advertising related to Novo Nordisk's grant.

### 3. Payment and Invoice Requirements

**3.1 Payment after receipt of invoice.** Novo Nordisk will send payment after receipt of invoice to the Recipient's bank account via electronic transfer within 30 days of receiving a complete invoice. Send completed PDF invoice to: [AP-Novio-Repas@novonordisk.com](mailto:AP-Novio-Repas@novonordisk.com). Include the below information on the invoice:

- Recipient name and address
- Bank account for electronic payment: Account holder name, account number (IBAN), bank name and address, routing number or code (SWIFT/BIC in EU, ABA/ACH in USA)
- Date of invoice
- The Title of Activity and dates of activities covered by the invoice
- Grant amount payable
- VAT or other tax amount payable (include separately from payment amount)
- Name of Novo Nordisk entity and address as stated in the introduction of this Agreement
- Novo Nordisk recipient of invoice as included below:

Name of Novo Nordisk invoice recipient    Søren Beicker Sørensen (BSBS)

### 4. Other Terms and Conditions

**4.1 Disclosure of Transfers of Value.** To comply with applicable transparency requirements, Novo Nordisk will collect and may disclose personal information, transfers of value and details of its payment to Healthcare Professionals ("HCPs") and Healthcare Organizations ("HCOs"). In addition to the payment amount, such disclosure may also include: Name, address, contact details, nature of relationship with Novo Nordisk, tax number or unique identifier.

**4.2 No conflict of interest.** Recipient states it is not aware of any conflict of interest related to its acceptance of the grant and shall promptly inform Novo Nordisk if such conflict of interest is discovered.

**4.3 Compliance hotline.** The Recipient can report suspected misconduct through the Novo Nordisk compliance hotline. Information about using the hotline and examples of what to report can be found at [Report suspected misconduct \(novonordisk.com\)](https://report.suspected.misconduct.novonordisk.com).

**4.4 No incentive to prescribe or recommend.** The payments made by Novo Nordisk indicate no incentive or obligation for the Recipient to prescribe, recommend or otherwise support Novo Nordisk's products or services.

**4.5 Termination for breach.** Either party may terminate this contract immediately upon material breach by the other party.

**4.6 Governing Law and Dispute Resolution.** The laws of Denmark govern this agreement, disregarding choice of law rules. If a dispute cannot be settled by negotiation between parties, it will be settled by the ordinary courts in that country.

5. Agreed to and accepted by:

Date: august 21, 2026

Date: August 17, 2026

On behalf of Recipient:

  
310CDFAFA3DD483...

Name: Eva Tingkær

Title: Vice Director

On behalf of Novo Nordisk:

  
D6C3B77D06B64DC

Name: Markus Hochmuth Petersen

Title: Senior Director

## Appendix A: Recipient's Request for Support

### 1. Copy of the Recipient's grant request

#### Ansøgning om støtte til Christiansborg-konference

Diabetesforeningen afholder den 24. september 2026 Sundhedspolitisk Åbningsdebat (SPÅ) for femte gang. Formålet med konferencen er - årligt - at rammesætte en bredere sundhedspolitisk debat lige op til Folketingets åbning. I år vil konferencen sætte fokus på debatten om sundhedsinvesteringer - og hvorfor sundhed kun betragtes som en udgift, mens de samfundsmæssige gevinster af bedre forebyggelse og behandling ikke spiller en særlig stor rolle, når politikerne, finansministeriet, kommuner og regioner prioriterer og beregner.

Herudover vil konferencen følge op på initiativer i sundhedsreformen her-under kronikerpakkerne og etableringen af sundhedsråd.

Konferencen vil lægge scene til politikere fra hhv. Christiansborg, kommuner og regioner samt eksperter og andre organisationer, der kan perspektivere og debattere temaerne.

Konferencen vil løbe af stablen den 24. september 2026, og MF Lea Wermelin, sundhedsordfører for Socialdemokratiet, vil være vært.

Vi forventer, at Lea Wermelin fortsat vil være vært efter folketingsvalget, men er naturligvis opmærksomme på at få det genbekræftet i den nye valgperiode.

Periode: 24. september 2026

Samlet projektbudget: 235.000 kr.

Anmodning om støtte fra Novo Nordisk på 96.000 kr. inkl moms.

Der søges ligeledes økonomisk støtte hos Boehringer Ingelheim og Sanofi til Sundhedspolitisk Åbningsdebat 2026. Den finansielle støtte skal bruges til at dække en del af Diabetesforeningens udgifter i forbindelse med konferencen samt udgifter til delvis moms (Diabetesforeningen har kun mulighed for at trække 17 % af momsdelen fra vores udgifter).

#### Udgift:

|                                                                        | Estimeret pris |
|------------------------------------------------------------------------|----------------|
| Moderator                                                              | 35.000 kr.     |
| Transportudgifter og honorar til oplægsholdere (ikke sundhedspersoner) | 20.000 kr.     |
| Trykomkostninger                                                       | 25.000 kr.     |
| Omkostninger til moms                                                  | 16.000         |
| I alt                                                                  | 96.000 kr.     |

**Appendix B: Agenda – draft**

## **Sundhedspolitisk Åbningsdebat 2026**

### **Investerings i et sundere Danmark**

Dato: 24. September 2026

Tid: Kl. 09.00-13.15

**Vært:** Lea Wermelin (TBC igen efter regeringsdannelse)

**Moderator:** Noa Redington [bekræftet]

#### **PROGRAM - UDKAST**

|             |                                                                                                                                                                                                                                              |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 09.00-09.15 | <b>Åbningsstale</b> v/ Sundhedsministeren [TBC]                                                                                                                                                                                              |
| 09.15-09.20 | <b>Velkommen</b> v/ Lea Wermelin [TBC]                                                                                                                                                                                                       |
| 09.20-09.35 | <b>Teknologiløftet - fra postnummerlotteri og pilotprojekter til samfundsforandrende investeringer i sundhed</b> v/ Claus Richter                                                                                                            |
| 09.35-09.50 | <b>Video m patientcases: Når sundhedsteknologi ændrer livet</b>                                                                                                                                                                              |
| 09.50-10.05 | <b>Underinvesterer Danmark i sundhed?</b><br><br><i>Forslag til oplægsholder: Ulrik Vestergaard [TBC] / International økonom [TBC]</i>                                                                                                       |
| 10.05-10.30 | <b>Politisk debat: Er investeringsbenspænd - sundhedsreformens værste fjende?</b><br><br><i>Sundhedsordførere vs Finansordførere (2 af hver, herunder Lea Wermelin) [TBC]</i>                                                                |
| 10.30-10.45 | <b>PAUSE</b>                                                                                                                                                                                                                                 |
| 10.45-11.15 | <b>Fra pilotprojekter til standardbehandling og reelle gevinster for patienter og samfund</b><br><br><i>To korte oplæg fra behandlere v/ Janne Heldbo, diabetessygeplejerske, Hillerød [TBC] og Morten Charles, praktiserende læge [TBC]</i> |
| 11.15-11.45 | <b>Politisk Debat: Finanslovsforhandlinger – live</b><br><br><i>3-4 finansordførere og evt. 1-2 andre til at udfordre (fx Mickael Bech, Michael Svarer, Lars Andersen (AE), Brian Mikkelsen, Claus Richter, anden patientforening) [TBC]</i> |
| 11.45-12.00 | <b>Opsamling og afrunding</b>                                                                                                                                                                                                                |

12.00 - 13.00

**Frokost to go & netværk**

## Certificate Of Completion

Envelope Id: 37D91272-887B-8A85-8265-18E16AA71B27

Status: Completed

Subject: Contract 667674 'Diabetesforening\_2026\_grant\_sundhedspolitisk-aabningsdebat' requires your action

Source Envelope:

Document Pages: 7

Signatures: 2

Envelope Originator:

Certificate Pages: 9

Initials: 0

Sari Kaarina Clausen

AutoNav: Enabled

Novo Allé, 2880 Bagsværd

Envelopeld Stamping: Enabled

Copenhagen, 2300

Time Zone: (UTC+01:00) Brussels, Copenhagen, Madrid, Paris

sqkf@novonordisk.com

IP Address: 54.246.251.198

## Record Tracking

Status: Original

Holder: Sari Kaarina Clausen

Location: DocuSign

8/17/2026 12:21:22 PM

sqkf@novonordisk.com

## Signer Events

Markus Peter Hochmuth

mrph@novonordisk.com

Senior MAPA Director

Security Level: Email, Account Authentication  
(None)

## Signature

DocuSigned by:  
  
D6C3B77D06B64DC...

Signature Adoption: Drawn on Device  
Using IP Address: 176.22.219.143  
Signed using mobile

## Timestamp

Sent: 8/17/2026 12:40:09 PM

Viewed: 8/17/2026 12:44:45 PM

Signed: 8/17/2026 12:44:54 PM

## Electronic Record and Signature Disclosure:

Accepted: 11/26/2024 3:04:14 PM

ID: b9c69c48-27c9-46ec-9612-4df2770d58ba

Company Name: Novo Nordisk A/S

Eva Tingkær

eva@diabetes.dk

Head of Public Affairs

Security Level: Email, Account Authentication  
(None)

DocuSigned by:  
  
310CDFAFA3DD483...

Signature Adoption: Pre-selected Style  
Using IP Address: 152.115.68.2

Sent: 8/17/2026 12:44:57 PM

Resent: 8/21/2026 8:48:50 AM

Viewed: 8/21/2026 9:26:20 AM

Signed: 8/21/2026 9:27:28 AM

## Electronic Record and Signature Disclosure:

Accepted: 8/29/2023 3:36:40 PM

ID: c94d6767-a1e6-4a93-ad7f-b4769796116c

Company Name: Novo Nordisk A/S

## In Person Signer Events

## Signature

## Timestamp

## Editor Delivery Events

## Status

## Timestamp

## Agent Delivery Events

## Status

## Timestamp

## Intermediary Delivery Events

## Status

## Timestamp

## Certified Delivery Events

## Status

## Timestamp

## Carbon Copy Events

## Status

## Timestamp

## Witness Events

## Signature

## Timestamp

## Notary Events

## Signature

## Timestamp

## Envelope Summary Events

## Status

## Timestamps

| Envelope Summary Events                    | Status           | Timestamps            |
|--------------------------------------------|------------------|-----------------------|
| Envelope Sent                              | Hashed/Encrypted | 8/17/2026 12:40:09 PM |
| Certified Delivered                        | Security Checked | 8/21/2026 9:26:20 AM  |
| Signing Complete                           | Security Checked | 8/21/2026 9:27:28 AM  |
| Completed                                  | Security Checked | 8/21/2026 9:27:28 AM  |
| Payment Events                             | Status           | Timestamps            |
| Electronic Record and Signature Disclosure |                  |                       |

## **ELECTRONIC RECORD AND SIGNATURE DISCLOSURE**

From time to time, Novo Nordisk (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

### **Getting paper copies**

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

### **Withdrawing your consent**

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

### **Consequences of changing your mind**

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

### **All notices and disclosures will be sent to you electronically**

Unless you tell us otherwise in accordance with the procedures described herein, we will provide

electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

#### **How to contact Novo Nordisk:**

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: [coupasysmgmt@novonordisk.com](mailto:coupasysmgmt@novonordisk.com)

#### **To advise Novo Nordisk of your new email address**

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at [coupasysmgmt@novonordisk.com](mailto:coupasysmgmt@novonordisk.com) and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

#### **To request paper copies from Novo Nordisk**

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to [coupasysmgmt@novonordisk.com](mailto:coupasysmgmt@novonordisk.com) and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

#### **To withdraw your consent with Novo Nordisk**

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to [coupasysmgmt@novonordisk.com](mailto:coupasysmgmt@novonordisk.com) and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

### **Required hardware and software**

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

### **Acknowledging your access and consent to receive and sign documents electronically**

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to ‘I agree to use electronic records and signatures’ before clicking ‘CONTINUE’ within the DocuSign system.

By selecting the check-box next to ‘I agree to use electronic records and signatures’, you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Novo Nordisk as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Novo Nordisk during the course of your relationship with Novo Nordisk.

## **NOTICE OF PERSONAL DATA PROCESSING**

Novo Nordisk A/S is required by law to protect your personal data. This Notice explains how we process (e.g. collect, use, store, and share) your personal data. We will process any personal data about you in accordance with this Notice and with applicable law.

## **1. WHO ARE WE?**

The company responsible for processing your personal data is:

Novo Nordisk A/S

Novo Allé 1

2880 Bagsværd

CVR Nr. 24256790

Tel: +45 4444 8888

You can always contact Novo Nordisk A/S or the Novo Nordisk Data Privacy Officer at [privacy@novonordisk.com](mailto:privacy@novonordisk.com) with questions or concerns about how we process your personal data.

## **2. HOW DO WE COLLECT PERSONAL DATA ABOUT YOU?**

We get your personal data from the following sources:

- From you directly

## **3. WHY DO WE PROCESS YOUR PERSONAL DATA?**

We process personal data about you for the following purposes:

- Business transactions, in particular execution of agreements with our suppliers, customers and other business partners
- To meet legal, financial and regulatory obligations

You are not required to provide us with your personal data. If you do not want Novo Nordisk to use your personal data, we will not be able to use electronic signature for your transactions.

#### **4. WHAT PERSONAL DATA DO WE PROCESS ABOUT YOU?**

For the purposes described above in Section 3, we may process the following types of personal data:

- Contact information (name, address, telephone number, email address);
- Work information (initials, e-mail address, job title, telephone number);
- Signature;
- IP address

#### **5. WHY ARE WE ALLOWED BY LAW TO PROCESS YOUR PERSONAL DATA?**

Our processing of your personal data requires a legal basis. By law, we are allowed to process your personal data described above in Section 4 based on the following legal bases:

- The processing is necessary for our legitimate interests. The legitimate interests are entering into contracts efficiently and ensuring documentation for our business transactions.

#### **6. HOW DO WE SHARE YOUR PERSONAL DATA?**

We may share your personal data with:

- Suppliers or vendors that assist our company (e.g., consultants, IT service providers, financial institutions, law firms, license partners)
- Other Novo Nordisk entities (e.g., Novo Nordisk affiliates in other countries)
- Public authorities

#### **7. WHEN DO WE TRANSFER YOUR PERSONAL DATA OUTSIDE THE EU/EAA?**

For the purposes described above in Section 3, we transfer your personal data to countries outside the European Economic Area (EEA). The level of data protection in certain countries outside the EEA does not conform to the level of data protection for personal data currently applied and enforced within the EEA..

We therefore use the following safeguards, as required by law, to protect your personal data in case of such transfers:

- The transfer is to a Novo Nordisk entity covered by Novo Nordisk's Binding Corporate Rules, available at <https://www.novonordisk.com/content/dam/nncorp/global/en/data-privacy/novo-nordisk-binding-corporate-rules.pdf>
- The destination countries are deemed by the EU Commission to have an adequate level of protection of personal data
- We have entered into Standard Contractual Clauses for the Transfer of Personal Data to Third Countries. You can get a copy of the Clauses by contacting us as described in Section 1

## **8. HOW LONG WILL WE KEEP YOUR PERSONAL DATA?**

We will keep your personal data for the following period of time:

- For a period of 10 years from the date of signature, and in case of healthcare regulated contracts, 50 years

## **9. WHAT ARE YOUR RIGHTS?**

In general, you have the following rights:

- You can get an overview of what personal data we have about you
- You can get a copy of your personal data in a structured, commonly used and machine-readable format
- You can get an update or correction to your personal data
- You can have your personal data deleted or destroyed
- You can have us stop or limit processing of your personal data

- If you have given consent for us to process your personal data (see Section 5), you can withdraw your consent at any time. Your withdrawal will not affect the lawfulness of the processing carried out before you withdrew your consent

- You can submit a complaint about how we process your personal data to a Data Protection Authority.

Under applicable law, there may be limits on these rights depending on the specific circumstances of the processing activity. Contact us as described in Section 1 with questions or requests relating to these rights.